Rahman Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rahman Shah has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
Abdul Rashid
Department of Medicine, Alabama College of Osteopathic Medicine, Dothan, Alabama
16 shared publicationsSunil V. Rao
Duke Clinical Research Institute, Durham, NC
9 shared publicationsAjay Labroo
Department of Medicine, Alabama College of Osteopathic Medicine, Dothan, Alabama
6 shared publicationsFrancis K. Le
Department of Medicine, Alabama College of Osteopathic Medicine, Dothan, Alabama
5 shared publicationsM. Rehan Khan
Department of Radiology, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
5 shared publicationsRaza Askari
Department of Medicine, University of Tennessee, Memphis, Tennessee
5 shared publications
Latest Publications
- 5 August 2024
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 20 (1) , 307-308
Fever induced ST-elevation in precordial leads: not to be confused with STEMI
- 5 August 2024
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 20 (1) , 307-308
Fever induced ST-elevation in precordial leads: not to be confused with STEMI
- 17 August 2023
- Published by Elsevier in The Lancet
- Vol. 402 (10402) , 610-611
Complete revascularisation in patients with acute coronary syndrome
- 17 August 2023
- Published by Elsevier in The Lancet
- Vol. 402 (10402) , 610-611
Complete revascularisation in patients with acute coronary syndrome
- 28 July 2023
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 34 (7) , 520-521
Impact of bivalirudin with a post-procedure infusion versus heparin-monotherapy on stent thrombosis and cardiovascular mortality
- 28 July 2023
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 34 (7) , 520-521
Impact of bivalirudin with a post-procedure infusion versus heparin-monotherapy on stent thrombosis and cardiovascular mortality
- 3 September 2021
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 33 (4) , 331-332
Percutaneous coronary intervention prevents spontaneous myocardial infarction in patients with stable coronary artery disease
An abstract is unavailable. This article is available as a PDF only.
- 3 September 2021
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 33 (4) , 331-332
Percutaneous coronary intervention prevents spontaneous myocardial infarction in patients with stable coronary artery disease
An abstract is unavailable. This article is available as a PDF only.
- 22 April 2021
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 78 (1) , e40-e44
A Meta-analysis of Clinical Trials Evaluating the Impact of Bivalirudin-based Anticoagulation for Primary Percutaneous Coronary on Long-Term Mortality
Bivalirudin and heparin are the principal anticoagulants used during primary percutaneous coronary intervention (PCI) for patients experiencing ST-elevation myocardial infarctions. Based on previous meta-analyses, bivalirudin improves 30-day mortality rates compared with heparin, especially when vascular access is predominantly femoral. However, no meta-analysis has yet reported whether this mortality benefit with bivalirudin persists beyond 30 days. Scientific databases and websites were searched to find randomized controlled trials, and risk ratios (RRs) were calculated using random effect models. Data from 4 trials were analyzed. Compared with heparin ± glycoprotein IIb/IIIa inhibitors, bivalirudin decreased all-cause mortality [RR, 0.81; 95% confidence interval (CI), 0.69–0.94; P = 0.008], cardiac mortality (RR, 0.72; 95% CI, 0.60–0.88; P = 0.001), and net adverse clinical events (RR, 0.83; 95% CI, 0.72–0.97; P = 0.016) at 1 year. In conclusion, a bivalirudin-based anticoagulation strategy during primary percutaneous coronary intervention significantly decreases the 1-year risks for all-cause mortality, cardiac mortality, and net adverse clinical events compared with heparin ± glycoprotein IIb/IIIa inhibitor.
- 22 April 2021
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 78 (1) , e40-e44
A Meta-analysis of Clinical Trials Evaluating the Impact of Bivalirudin-based Anticoagulation for Primary Percutaneous Coronary on Long-Term Mortality
Bivalirudin and heparin are the principal anticoagulants used during primary percutaneous coronary intervention (PCI) for patients experiencing ST-elevation myocardial infarctions. Based on previous meta-analyses, bivalirudin improves 30-day mortality rates compared with heparin, especially when vascular access is predominantly femoral. However, no meta-analysis has yet reported whether this mortality benefit with bivalirudin persists beyond 30 days. Scientific databases and websites were searched to find randomized controlled trials, and risk ratios (RRs) were calculated using random effect models. Data from 4 trials were analyzed. Compared with heparin ± glycoprotein IIb/IIIa inhibitors, bivalirudin decreased all-cause mortality [RR, 0.81; 95% confidence interval (CI), 0.69–0.94; P = 0.008], cardiac mortality (RR, 0.72; 95% CI, 0.60–0.88; P = 0.001), and net adverse clinical events (RR, 0.83; 95% CI, 0.72–0.97; P = 0.016) at 1 year. In conclusion, a bivalirudin-based anticoagulation strategy during primary percutaneous coronary intervention significantly decreases the 1-year risks for all-cause mortality, cardiac mortality, and net adverse clinical events compared with heparin ± glycoprotein IIb/IIIa inhibitor.
- 19 April 2021
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 33 (2) , 91-97
A meta-analysis of optimal medical therapy with or without percutaneous coronary intervention in patients with stable coronary artery disease
Background: Whether percutaneous coronary intervention (PCI) improves clinical outcomes in patients with chronic angina and stable coronary artery disease (CAD) has been a continuing area of investigation for more than two decades. The recently reported results of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches, the largest prospective trial of optimal medical therapy (OMT) with or without myocardial revascularization, provides a unique opportunity to determine whether there is an incremental benefit of revascularization in stable CAD patients. Methods: Scientific databases and websites were searched to find randomized clinical trials (RCTs). Pooled risk ratios were calculated using the random-effects model. Results: Data from 10 RCTs comprising 12 125 patients showed that PCI, when added to OMT, were not associated with lower all-cause mortality (risk ratios, 0.96; 95% CI, 0.87–1.08), cardiovascular mortality (risk ratios, 0.91; 95% CI, 0.79–1.05) or myocardial infarction (MI) (risk ratios, 0.90; 95% CI, 0.78–1.04) as compared with OMT alone. However, OMT+PCI was associated with improved anginal symptoms and a lower risk for revascularization (risk ratios, 0.52; 95% CI, 0.37–0.75). Conclusions: In patient with chronic stable CAD (without left main disease or reduced ejection fraction), PCI in addition to OMT did not improve mortality or MI compared to OMT alone. However, this strategy is associated with a lower rate of revascularization and improved anginal symptoms.
- 19 April 2021
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 33 (2) , 91-97
A meta-analysis of optimal medical therapy with or without percutaneous coronary intervention in patients with stable coronary artery disease
Background: Whether percutaneous coronary intervention (PCI) improves clinical outcomes in patients with chronic angina and stable coronary artery disease (CAD) has been a continuing area of investigation for more than two decades. The recently reported results of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches, the largest prospective trial of optimal medical therapy (OMT) with or without myocardial revascularization, provides a unique opportunity to determine whether there is an incremental benefit of revascularization in stable CAD patients. Methods: Scientific databases and websites were searched to find randomized clinical trials (RCTs). Pooled risk ratios were calculated using the random-effects model. Results: Data from 10 RCTs comprising 12 125 patients showed that PCI, when added to OMT, were not associated with lower all-cause mortality (risk ratios, 0.96; 95% CI, 0.87–1.08), cardiovascular mortality (risk ratios, 0.91; 95% CI, 0.79–1.05) or myocardial infarction (MI) (risk ratios, 0.90; 95% CI, 0.78–1.04) as compared with OMT alone. However, OMT+PCI was associated with improved anginal symptoms and a lower risk for revascularization (risk ratios, 0.52; 95% CI, 0.37–0.75). Conclusions: In patient with chronic stable CAD (without left main disease or reduced ejection fraction), PCI in addition to OMT did not improve mortality or MI compared to OMT alone. However, this strategy is associated with a lower rate of revascularization and improved anginal symptoms.
- 1 December 2020
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 180 (12) , 1685-1686
A Man With a Sixth Wave in Electrocardiogram Results
This case report describes a 39-year-old man with a short history of subjective fever, lethargy, cough, nausea, and vomiting.
- 1 December 2020
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 180 (12) , 1685-1686
A Man With a Sixth Wave in Electrocardiogram Results
This case report describes a 39-year-old man with a short history of subjective fever, lethargy, cough, nausea, and vomiting.
- 1 November 2020
- Published by Elsevier in The American Journal of Cardiology
- Vol. 134, 69-73
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia
- 1 November 2020
- Published by Elsevier in The American Journal of Cardiology
- Vol. 134, 69-73
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia
- 26 August 2020
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 98 (3) , E490-E492
Increased risk of stent thrombosis with use of a direct oral anticoagulant and a single antiplatelet agent after PCI: A meta‐analysis
- 26 August 2020
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 98 (3) , E490-E492
Increased risk of stent thrombosis with use of a direct oral anticoagulant and a single antiplatelet agent after PCI: A meta‐analysis